New Drug Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer Patients

Scientists report that daraxonrasib, a drug targeting the KRAS mutation present in most pancreatic cancers, has nearly doubled survival rates in advanced-stage patients in landmark clinical trials.